Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,229 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Regulatory T cells in cancer immunotherapy.
Nishikawa H, Sakaguchi S. Nishikawa H, et al. Curr Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14. Curr Opin Immunol. 2014. PMID: 24413387 Review.
Regulatory T cells in tumor immunity.
Nishikawa H, Sakaguchi S. Nishikawa H, et al. Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429. Int J Cancer. 2010. PMID: 20518016 Review.
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. Saito T, et al. Vaccine. 2014 Oct 14;32(45):5901-7. doi: 10.1016/j.vaccine.2014.09.002. Epub 2014 Sep 13. Vaccine. 2014. PMID: 25218300 Clinical Trial.
Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
Hirayama M, Nishikawa H, Nagata Y, Tsuji T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjatic S, Shiku H. Hirayama M, et al. Eur J Immunol. 2013 Apr;43(4):989-1000. doi: 10.1002/eji.201242800. Epub 2013 Feb 26. Eur J Immunol. 2013. PMID: 23436617
Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.
Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S, Old LJ, Shiku H, Nishikawa H. Noguchi T, et al. Cancer Res. 2012 Apr 1;72(7):1672-82. doi: 10.1158/0008-5472.CAN-11-3072. Epub 2012 Feb 8. Cancer Res. 2012. PMID: 22318866
UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses.
Toda M, Wang L, Ogura S, Torii M, Kurachi M, Kakimi K, Nishikawa H, Matsushima K, Shiku H, Kuribayashi K, Kato T. Toda M, et al. Int J Cancer. 2011 Sep 1;129(5):1126-36. doi: 10.1002/ijc.25775. Epub 2011 Jan 12. Int J Cancer. 2011. PMID: 21710495
IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.
Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Old LJ, Shiku H. Nishikawa H, et al. J Immunol. 2005 Oct 1;175(7):4433-40. doi: 10.4049/jimmunol.175.7.4433. J Immunol. 2005. PMID: 16177085
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.
Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H. Nishikawa H, et al. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9253-7. doi: 10.1073/pnas.0503852102. Epub 2005 Jun 16. Proc Natl Acad Sci U S A. 2005. PMID: 15961541 Free PMC article.
Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells.
Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, Shiku H. Nishikawa H, et al. J Exp Med. 2005 Mar 7;201(5):681-6. doi: 10.1084/jem.20041959. J Exp Med. 2005. PMID: 15753203 Free PMC article.
1,229 results
Jump to page
Feedback